Illumina (NASDAQ:ILMN) Stock Price Expected to Rise, Stephens Analyst Says

Illumina (NASDAQ:ILMN - Free Report) had its target price raised by Stephens from $170.00 to $184.00 in a report published on Tuesday morning,Benzinga reports. The brokerage currently has an overweight rating on the life sciences company's stock.

A number of other research firms have also recently weighed in on ILMN. UBS Group lifted their price objective on Illumina from $133.00 to $145.00 and gave the company a "neutral" rating in a research report on Tuesday, November 5th. Piper Sandler lowered their target price on Illumina from $195.00 to $185.00 and set an "overweight" rating for the company in a report on Monday. Royal Bank of Canada upped their price objective on Illumina from $252.00 to $254.00 and gave the stock an "outperform" rating in a research note on Tuesday, November 5th. Daiwa Capital Markets raised Illumina from a "neutral" rating to a "buy" rating and increased their price objective for the company from $120.00 to $154.00 in a report on Friday, August 16th. Finally, Robert W. Baird raised their target price on Illumina from $124.00 to $139.00 and gave the stock a "neutral" rating in a report on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $164.00.

Illumina Price Performance

NASDAQ ILMN traded down $3.88 on Tuesday, reaching $147.62. 2,021,892 shares of the company's stock traded hands, compared to its average volume of 2,003,543. The stock has a market cap of $23.41 billion, a PE ratio of -15.21 and a beta of 1.13. Illumina has a 12 month low of $92.26 and a 12 month high of $156.66. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 0.86. The stock has a 50-day simple moving average of $138.50 and a 200 day simple moving average of $123.77.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating the consensus estimate of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The business had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. During the same quarter last year, the firm posted $0.33 earnings per share. The company's revenue for the quarter was down 3.5% on a year-over-year basis. As a group, research analysts predict that Illumina will post 4.11 earnings per share for the current year.

Institutional Trading of Illumina

Several hedge funds and other institutional investors have recently bought and sold shares of ILMN. Vanguard Group Inc. boosted its position in Illumina by 0.4% in the first quarter. Vanguard Group Inc. now owns 18,245,041 shares of the life sciences company's stock valued at $2,505,409,000 after buying an additional 66,528 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Illumina by 7.2% in the second quarter. Bank of New York Mellon Corp now owns 3,039,538 shares of the life sciences company's stock valued at $317,267,000 after buying an additional 204,043 shares during the period. Capital World Investors boosted its holdings in shares of Illumina by 41.1% in the first quarter. Capital World Investors now owns 2,753,504 shares of the life sciences company's stock valued at $378,111,000 after buying an additional 801,814 shares during the period. Primecap Management Co. CA boosted its holdings in Illumina by 3.6% during the third quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company's stock worth $328,158,000 after purchasing an additional 87,599 shares during the last quarter. Finally, GUARDCAP ASSET MANAGEMENT Ltd boosted its holdings in Illumina by 1.1% during the first quarter. GUARDCAP ASSET MANAGEMENT Ltd now owns 2,068,869 shares of the life sciences company's stock worth $284,097,000 after purchasing an additional 22,067 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.